Seattle, July 13, 2022 /PRNewswire/ — According to Coherent Market Insights, the global Crohn’s disease treatment market is estimated to be valued at $10.92 billion In 2022, it is expected to grow at a CAGR of 4.2% during the forecast period (2022-2030).
Key Trends and Analysis of the Global Crohn’s Disease Treatment Market:
Key players in the market are focusing on adopting strategies such as product approval, which is expected to drive market growth over the forecast period.For example, in June 2019Biopharmaceutical company Amgen announced that the U.S. Food and Drug Administration (FDA) has approved AVSOLA (infliximab-axxq) for all approved indications for the reference product Remicade (infliximab) for the treatment of moderate-to-adult and pediatric populations Severe Crohn’s disease (CD) in
Market dynamics
This North America and Europe Regions with high incidence of inflammatory bowel disease (IBD), such as Crohn’s disease, are expected to drive market growth. For example, according to an article published in the journal Digestive Medicine Research, December 2020exist North America, the prevalence of IBD is expected to affect approximately 4 million people by 2030.According to the same source, from Canada The prevalence of IBD was reported to be 725 per 100,000 in 2018 and is expected to rise to 981 by 2030. Hence, the increasing prevalence of IBD is expected to drive the market growth over the forecast period.
Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/1237
Key Market Highlights:
The global Crohn’s disease treatment market is expected to compound over the forecast period owing to the increasing adoption of inorganic strategies such as key players collaborating to develop new treatments for inflammatory bowel disease (IBD) such as Crohn’s disease and ulcerative The annual growth rate was 4.2% for colitis.For example, in April 2022Inotrem, an advanced clinical-stage biotechnology company specializing in immunotherapies for acute and chronic inflammatory syndromes, announced a research and development collaboration agreement with the Crohn’s and Colitis Foundation to support the development of a novel treatment in IBD method.
the story continues
Among drug types, immunomodulators segment dominates the global Crohn’s disease treatment market due to its better therapeutic effects. However, the main benefit of these drugs is to reduce the long-term need for steroids and prevent relapse. For this reason, immunomodulators are sometimes called “steroid-sparing” drugs. They can also be used in combination with other drugs, such as biologics, to help prevent antibody formation, which can lead to a loss of response to biologics.
On the basis of distribution channel, the hospital pharmacy segment is expected to dominate the global Crohn’s disease treatment market owing to the increasing number of patients coming to hospitals to inquire about Crohn’s disease-related treatments.For example, according to an article published by WebMD LLC, which publishes information about human health and well-being online, at June 2020up to 80% of people with Crohn’s disease require hospitalization at some point
Key players operating in the global Crohn’s disease treatment market include AbbVie Inc., Janssen Biotech, Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Pfizer Inc., Eli Lilly and Company, Novartis AG, Sanofi, Takeda Pharmaceutical Company Limited, Mylan NV, Amgen Corporation and AstraZeneca.
Customization Request @ https://www.coherentmarketinsights.com/insight/request-customization/1237
Detailed breakdown:
Global Crohn’s Disease Treatment Market, By Drug Type:
Global Crohn’s Disease Treatment Market, By Distribution Channel:
Global Crohn’s Disease Treatment Market, By Region:
Buy this full report now @ https://www.coherentmarketinsights.com/insight/buy-now/1237
about us:
Coherent Market Insights is a global market intelligence and consulting agency dedicated to helping our many clients achieve transformational growth by helping them make critical business decisions.Our headquarters are located in Indiawith sales offices in Global Financial Capital in the U.S. and sales consultants in the U.S. U.K. and Japan. Our client base includes players from various verticals in more than 57 countries around the world. We create value for our clients through highly reliable and accurate reporting. We are also committed to taking a leading role in delivering insights across post-COVID-19 areas and continuing to deliver measurable, sustainable outcomes for our clients.
Contact Us: Mr. Shah Senior Client Partner – Business Development Coherent Market Insights Tel: US: +1-206-701-6702 UK: +44-020-8133-4027Japan: +81-050-5539-1737India: +91-848-285-0837 Email: [email protected] Website: https://www.coherentmarketinsights.com Follow us: LinkedIn | Twitter
Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/global-crohns-disease-treatment-market-to-surpass-us-15-17-billion-by-2030–coherent-market-insights -301585710.html
Source-consistent market insights
